These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33970738)

  • 1. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
    Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
    Nozawa K; Terada M; Onishi M; Ozaki Y; Takano T; Fakhouri W; Novick D; Haro JM; Faris LH; Kawaguchi T; Tanizawa Y; Tsurutani J
    Breast Cancer; 2023 Jul; 30(4):657-665. PubMed ID: 37217763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho A; Rybowski S
    Adv Ther; 2023 May; 40(5):2515-2523. PubMed ID: 36995468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
    Smyth EN; Beyrer J; Saverno KR; Hadden E; Abedtash H; DeLuca A; Lawrence GW; Rybowski S
    Drugs Real World Outcomes; 2022 Dec; 9(4):681-693. PubMed ID: 36097254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.
    Matos E; Cankar K; Režun N; Dejanović K; Ovčariček T
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
    Blanch S; Gil-Gil JM; Arumí M; Aguirre E; Seguí MÁ; Atienza M; Díaz-Cerezo S; Molero A; Cervera JM; Gavilá J
    Clin Transl Oncol; 2023 Oct; 25(10):2950-2959. PubMed ID: 37029241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
    Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
    Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
    Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
    Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
    Tolaney SM; Sahebjam S; Le Rhun E; Bachelot T; Kabos P; Awada A; Yardley D; Chan A; Conte P; Diéras V; Lin NU; Bear M; Chapman SC; Yang Z; Chen Y; Anders CK
    Clin Cancer Res; 2020 Oct; 26(20):5310-5319. PubMed ID: 32694159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.